FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker

Reuters09-24

FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker

FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate $(ADC)$ targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534126-en) on September 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569703520?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569703520","market":"us","top_or_hot":-1,"title":"FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534126-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-24 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534126-en) on September 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FGEN","symbol_name":"FibroGen, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL5gs5jX:1","article_id":"2569703520","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569703520","pubTimestamp":1758711624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate  targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer . The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FGEN":"FibroGen, Inc","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4505":"高瓴资本持仓","BK4588":"碎股"},"translate_title":"FibroGen启动FG-3246治疗mCRPC的2期试验，评估FG-3180作为伴随PET成像生物标志物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FGEN":0.9,"NDAQ":0.9},"content_text":"FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker\n    \n\n        FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate $(ADC)$ targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9534126-en) on September 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569703520","isCrawlerRequest":true}